Brief: Nabriva Therapeutics Provides Business Update And Announces Preliminary Financial Results For The Fourth Quarter Of 2021
10/01/2022 12:10
Jan 10 (Reuters) - Nabriva Therapeutics PLC NBRV.O :
* NABRIVA THERAPEUTICS PROVIDES BUSINESS UPDATE AND ANNOUNCES PRELIMINARY
FINANCIAL RESULTS FOR THE FOURTH QUARTER OF 2021
* NABRIVA THERAPEUTICS PLC - XENLETA (LEFAMULIN) PHASE I CYSTIC FIBROSIS
(CF)
TRIAL ON TRACK TO ENROLL FIRST PATIENT IN Q122
* NABRIVA THERAPEUTICS PLC - CASH RESOURCES OF $47.7 MILLION AS OF DECEMBER
31,
2021 PROVIDES CASH RUNWAY WELL INTO Q422
* NABRIVA THERAPEUTICS PLC - SIVEXTRO(®) (TEDIZOLID PHOSPHATE) REMAINS ON
TRACK
FOR RETURN TO HISTORICAL PEAK SALES BY MID-2022
Source text for Eikon: ID:nGNX5ZyhGc
Further company coverage: NBRV.O
Recent news on Nabriva Therapeutics
See all newsBrief: Nabriva Therapeutics And Units Enter Asset Purchase Agreement With Sumitomo Pharma
Brief: Nabriva Therapeutics Says Received Delisting Determination Letter From Nasdaq
Brief: Nabriva Therapeutics Receives Notice Of Delisting Or Failure To Satisfy Continued Listing Rule From Nasdaq
Brief: Nabriva Therapeutics - On Jan 31, Co's Unit Entered Into Letter Agreement With 2 Units Of Merck & Co, About Distribution Agreement, Dated July 15, 2020
Brief: Nabriva Therapeutics Provides Corporate Update